Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Expanded CUG repeat RNA refers to abnormally long stretches of cytosine–uracil–guanine trinucleotide repeats found within the 3′ untranslated region (UTR) of certain mRNAs, most notably the DMPK gene transcript associated with myotonic dystrophy type 1 (DM1)[2][5]. These expanded repeats form highly stable hairpin secondary structures characterized by periodic U-U mismatches within an otherwise A-form double helix. The abnormal structure sequesters key regulatory proteins such as Muscleblind-like protein 1 (MBNL1), leading to widespread defects in pre-mRNA splicing and other aspects of post-transcriptional regulation[3][4][5]. Additionally, these RNAs can activate double-stranded-RNA binding proteins like PKR, triggering stress responses that further inhibit translation and contribute to disease pathology[1][6]. Therapeutic strategies are being developed that target these toxic RNAs using small molecules or antisense oligonucleotides designed either to disrupt their structure or promote their degradation. The length and presence of expanded CTG/CUG repeats serve as both a diagnostic marker for DM1 and a potential biomarker for therapeutic intervention efficacy. However, achieving selectivity without affecting normal cellular processes remains a significant challenge in drug development targeting this pathogenic non-coding RNA species.
Small molecule or oligonucleotide binding to expanded CUG repeats disrupts pathogenic hairpin structures or promotes cleavage/removal, thereby releasing sequestered proteins and restoring normal splicing/translation[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Expanded CUG repeat RNA.